Speaker Profile
Biography
David S. Liebeskind, MD, FAHA, FAAN is Professor of Neurology at the University of California, Los Angeles (UCLA) where he serves as the Associate Neurology Director of the UCLA Stroke Center and the Neurology Director of the Stroke Imaging Program. He is Co-Director of the UCLA Cerebral Blood Flow Laboratory and Director of the UCLA Vascular Neurology Residency Program.He trained in chemical engineering at Columbia University and completed his MD at New York University School of Medicine. Postgraduate medical training included internship at Beth Israel Hospital, Boston and neurology residency at UCLA. After his residency, he completed a fellowship in stroke and cerebrovascular disease at UCLA and subsequently joined the faculty in the Departments of Neurology and Radiology at the University of Pennsylvania.He has maintained extensive clinical activity across a broad range of cerebrovascular disorders ranging from carotid disease to unusual causes of stroke. Clinical expertise includes cerebral venous thrombosis, arterial dissection, moyamoya syndrome and other causes of stroke in the young. His principal research interests include novel neuroimaging approaches to elucidate fundamental pathophysiologic correlates of cerebrovascular disease in humans with a particular focus on the collateral circulation. His work on collateral perfusion in acute ischemic stroke draws on advances in noninvasive, multimodal CT and MRI and detailed analyses of digital subtraction angiography. He directs an angiography and imaging core laboratory that has participated in central readings of MERCI, Multi MERCI, IMS-III, TREVO EU and TREVO 2. His research on collaterals in intracranial atherosclerosis complements his work on acute stroke, utilizing computational fluid dynamic modeling and estimates of fractionalflow to predict risk of ischemia and reperfusion hemorrhage.
Session Abstract – PMWC 2027 Silicon Valley
Track Chair:
Ira Mellman, Medici Therapeutics
PMWC Award Ceremony
• Jedd D. Wolchok, Weill Cornell Medicine
• Suzanne Topalian, Johns Hopkins
• Levi Garraway, Roche
Keynote: Future Breakthroughs in Immuno-Oncology: New Targets, Modalities & Combinations
• Levi Garraway, Roche
Checkpoint 2.0 in Practice: PD-1+VEGF Wins, Resistance Salvage & Biomarker Gates
• Chair: Anne Kasmar, Parexel
• Jedd D. Wolchok, Weill Cornell Medicine
• Roy S. Herbst, Yale
• Nathan Fowler, BostonGene
Immunotherapy with Personalized Cancer Vaccines: Who, When, How Fast?
• Chair: Suzanne Topalian, Johns Hopkins
• Tal Zaks, Orbimed
• Lelia Delamarre, Genentech
The Next Era: Neutralizing On-Target, Off-Tumor Effects by Turning Cancer Against Itself
• Cyriac Roeding, Earli
Fireside Chat: Immune Tolerance to Cure, A Conversation With...
• Lee Hood, Institute for Systems Biology
• Mary E. Brunkow, Institute for Systems Biology
ADCs in the Checkpoint Era: Who Benefits, What to Combine, What to Avoid
• Chair: Shreya Badhrinarayanan, Pfizer
• Gerold Meinhardt, Daiichi Sankyo
• Vadim Koshkin, UCSF
Strategic IP Management in Cell and Gene Therapy: Navigating Legal and Practical Challenges
• Janet Xiao, Morrison & Foerster LLP
Targeting the Tumor Microenvironment (TME) in Practice: Biomarkers & Combos
• Chair: Ira Mellman, Medici Therapeutics
• Dmitry Gabrilovich, AstraZeneca
• Jennifer Mataraza, Novartis
• Nathan Fowler, BostonGene
• Christine Moussion, Genentech
Future Breakthroughs in TME Reprogramming: New Modalities, Smarter Delivery & Overcoming Resistance
• David Kirn, ReIGNITE
Radiopharmaceutical Therapy: New Targets, Isotopes, and Challenges
• Chair: William Oh, Yale
• Munir Ghesani, United Theranostics
• Sandy Srinivas, Stanford
• Anna Karmann, AdvanCell




